AB-161

• UNSPSC Description:

  AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research[1].

• Target Antigen:

  HBV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/ab-161.html

• Smiles:

  O=C(O)C1=CC2=C(C3=C(C[C@H]2C(C)(C)C)N4C(C(OC(F)F)=CC(OC)=C4)=N3)NC1=O

• Molecular Weight:

  433.41

• References & Citations:

  [1]Gotchev D, et al. Structure-Activity Relationships and Discovery of (S)-5-(tert-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-h]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer. J Med Chem. 2024 Nov 28;67(22):20467-20494.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2848560-66-5